Research graph
References from Safety profile of elafibranor versus placebo in primary biliary cholangitis. Local targets link to admitted publications; unresolved targets remain external evidence.
Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases.
10.1002/hep.30145 · 2019 · External reference
Primary biliary cholangitis.
10.1016/s0140-6736(20)31607-x · 2020 · External reference
Evolving trends in female to male incidence and male mortality of primary biliary cholangitis.
10.1038/srep25906 · 2016 · External reference
Primary biliary cholangitis: epidemiology, diagnosis, and presentation.
10.1016/j.cld.2023.06.005 · 2024 · External reference
The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis.
10.1002/hep.28017 · 2016 · External reference
Primary biliary cirrhosis has high wait-list mortality among patients listed for liver transplantation.
10.1111/tri.12877 · 2017 · External reference
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
10.1002/hep.22428 · 2008 · External reference
EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis.
10.1016/j.jhep.2017.03.022 · 2017 · External reference
A placebo-controlled trial of obeticholic acid in primary biliary cholangitis.
10.1056/nejmoa1509840 · 2016 · External reference
Efficacy and safety of obeticholic acid as second-line therapy in primary biliary cholangitis: systematic review and meta-analysis.
10.1111/jgh.70094 · 2025 · External reference
Elafibranor for primary biliary cholangitis: a dual PPAR agonist changing the treatment landscape.
10.1097/ms9.0000000000003395 · 2025 · External reference
Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study.
10.1053/j.gastro.2014.08.029 · 2014 · External reference
Efficacy and safety of elafibranor in primary biliary cholangitis.
10.1056/nejmoa2306185 · 2024 · External reference
A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
10.1016/j.jhep.2021.01.013 · 2021 · External reference
Second-line treatment for patients with primary biliary cholangitis: a systematic review with network meta-analysis.
10.1111/liv.16222 · 2025 · External reference
Efficacy and safety of novel oral anti-cholestatic agents for primary biliary cholangitis: meta-analyses and systematic review.
10.3390/ph18050697 · 2025 · External reference
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.
10.1136/bmj.n71 · 2021 · External reference
Rayyan-a web and mobile app for systematic reviews.
10.1186/s13643-016-0384-4 · 2016 · External reference
RoB 2: a revised tool for assessing risk of bias in randomised trials.
10.1136/bmj.l4898 · 2019 · External reference
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.
10.1136/bmj.39489.470347.ad · 2008 · External reference
Statistical aspects of the analysis of data from retrospective studies of disease.
1959 · External reference
Meta-analysis in clinical trials.
10.1016/0197-2456(86)90046-2 · 1986 · External reference
Estimating required information size by quantifying diversity in random-effects model meta-analyses.
10.1186/1471-2288-9-86 · 2009 · External reference
Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis.
10.1016/j.jclinepi.2007.03.013 · 2008 · External reference
Baseline alkaline phosphatase impacts response rates in primary biliary cholangitis: exploring response to elafibranor in ELATIVE.
10.1111/liv.70630 · 2026 · External reference
